Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus.

Ji H, Enns E, Brumme CJ, Parkin N, Howison M, Lee ER, Capina R, Marinier E, Avila-Rios S, Sandstrom P, Van Domselaar G, Harrigan R, Paredes R, Kantor R, Noguera-Julian M.

J Int AIDS Soc. 2018 Oct;21(10):e25193. doi: 10.1002/jia2.25193.

2.

Genotypic and Mechanistic Characterization of Subtype-specific HIV Adaptation to Host Cellular Immunity.

Kinloch NN, Lee GQ, Carlson JM, Jin SW, Brumme CJ, Byakwaga H, Muzoora C, Bwana MB, Cobarrubias KD, Hunt PW, Martin JN, Carrington M, Bangsberg DR, Harrigan PR, Brockman MA, Brumme ZL.

J Virol. 2018 Oct 10. pii: JVI.01502-18. doi: 10.1128/JVI.01502-18. [Epub ahead of print]

PMID:
30305354
3.

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population.

Valenzuela-Ponce H, Alva-Hernández S, Garrido-Rodríguez D, Soto-Nava M, García-Téllez T, Escamilla-Gómez T, García-Morales C, Quiroz-Morales VS, Tapia-Trejo D, Del Arenal-Sánchez S, Prado-Galbarro FJ, Hernández-Juan R, Rodríguez-Aguirre E, Murakami-Ogasawara A, Mejía-Villatoro C, Escobar-Urias IY, Pinzón-Meza R, Pascale JM, Zaldivar Y, Porras-Cortés G, Quant-Durán C, Lorenzana I, Meza RI, Palou EY, Manzanero M, Cedillos RA, Aláez C, Brockman MA, Harrigan PR, Brumme CJ, Brumme ZL, Ávila-Ríos S, Reyes-Terán G; Mesoamerican HIV Project Group.

Sci Rep. 2018 Apr 17;8(1):6111. doi: 10.1038/s41598-018-23849-7.

4.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

Penrose KJ, Brumme CJ, Scoulos-Hanson M, Hamanishi K, Gordon K, Viana RV, Wallis CL, Harrigan PR, Mellors JW, Parikh UM.

Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618762985. doi: 10.1177/2040206618762985.

5.

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, Brumme CJ, Foster BA, Jerene D, Makonnen E, Aklillu E, Brumme ZL.

Viruses. 2018 Feb 1;10(2). pii: E60. doi: 10.3390/v10020060.

6.

Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.

Soto-Nava M, Avila-Ríos S, Valenzuela-Ponce H, García-Morales C, Carlson JM, Tapia-Trejo D, Garrido-Rodriguez D, Alva-Hernández SN, García-Tellez TA, Murakami-Ogasawara A; International HIV Adaptation Collaborative, Mallal SA, John M, Brockman MA, Brumme CJ, Brumme ZL, Reyes-Teran G; HIV MexNet Group.

J Virol. 2018 Jan 2;92(2). pii: e01128-17. doi: 10.1128/JVI.01128-17. Print 2018 Jan 15.

7.

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.

Rocheleau G, Franco-Villalobos C, Oliveira N, Brumme ZL, Rusch M, Shoveller J, Brumme CJ, Harrigan PR.

PLoS One. 2017 Sep 22;12(9):e0184848. doi: 10.1371/journal.pone.0184848. eCollection 2017.

8.

Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches.

Lee GQ, Bangsberg DR, Mo T, Lachowski C, Brumme CJ, Zhang W, Lima VD, Boum Y 2nd, Mwebesa BB, Muzoora C, Andia I, Mbalibulha Y, Kembabazi A, Carroll R, Siedner MJ, Haberer JE, Mocello AR, Kigozi SH, Hunt PW, Martin JN, Harrigan PR.

AIDS. 2017 Nov 13;31(17):2345-2354. doi: 10.1097/QAD.0000000000001619.

PMID:
28832407
9.

Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.

Rocheleau G, Brumme CJ, Shoveller J, Lima VD, Harrigan PR.

Clin Microbiol Infect. 2018 Feb;24(2):185-191. doi: 10.1016/j.cmi.2017.06.014. Epub 2017 Jun 23.

PMID:
28652115
10.

Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity.

Naidoo VL, Mann JK, Noble C, Adland E, Carlson JM, Thomas J, Brumme CJ, Thobakgale-Tshabalala CF, Brumme ZL, Brockman MA, Goulder PJR, Ndung'u T.

J Virol. 2017 Aug 10;91(17). pii: e00518-17. doi: 10.1128/JVI.00518-17. Print 2017 Sep 1.

11.

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.

Gonzalez-Serna A, Glas AC, Brumme CJ, Poon AF, Nohpal De La Rosa A, Mudrikova T, Dias Lima V, Wensing AM, Harrigan R.

J Antimicrob Chemother. 2017 Feb;72(2):496-503. doi: 10.1093/jac/dkw455. Epub 2016 Dec 20.

PMID:
27999069
12.

Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.

Brumme CJ, Poon AFY.

Virus Res. 2017 Jul 15;239:97-105. doi: 10.1016/j.virusres.2016.12.008. Epub 2016 Dec 18. Review.

PMID:
27993623
13.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Penrose KJ, Wallis CL, Brumme CJ, Hamanishi KA, Gordon KC, Viana RV, Harrigan PR, Mellors JW, Parikh UM.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01805-16. doi: 10.1128/AAC.01805-16. Print 2017 Feb.

14.

Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase.

Telwatte S, Brumme CJ, Hearps AC, Latham CF, Hayward JA, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G.

AIDS. 2016 Nov 28;30(18):2787-2793.

PMID:
27677159
15.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

16.

Erratum to: Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.

Sakai K, Chikata T, Brumme ZL, Brumme CJ, Gatanaga H, Oka S, Takiguchi M.

Retrovirology. 2015 Nov 30;12:100. doi: 10.1186/s12977-015-0227-8. No abstract available.

17.
18.

HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.

Lapointe HR, Dong W, Lee GQ, Bangsberg DR, Martin JN, Mocello AR, Boum Y, Karakas A, Kirkby D, Poon AF, Harrigan PR, Brumme CJ.

Antimicrob Agents Chemother. 2015 Nov;59(11):6824-33. doi: 10.1128/AAC.01490-15. Epub 2015 Aug 17.

19.

Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.

Chui CK, Dong WW, Joy JB, Poon AF, Dong WY, Mo T, Woods CK, Beatty C, Hew H, Harrigan PR, Brumme CJ.

J Clin Microbiol. 2015 Sep;53(9):2942-50. doi: 10.1128/JCM.00650-15. Epub 2015 Jul 1.

20.

The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada.

Poon AF, Joy JB, Woods CK, Shurgold S, Colley G, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2015 Mar 15;211(6):926-35. doi: 10.1093/infdis/jiu560. Epub 2014 Oct 13.

21.

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Lee GQ, Bangsberg DR, Muzoora C, Boum Y, Oyugi JH, Emenyonu N, Bennett J, Hunt PW, Knapp D, Brumme CJ, Harrigan PR, Martin JN.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):896-906. doi: 10.1089/AID.2014.0043. Epub 2014 Jul 29.

22.

Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy.

Lee GQ, Dong W, Mo T, Knapp DJ, Brumme CJ, Woods CK, Kanters S, Yip B, Harrigan PR.

PLoS One. 2014 Jun 6;9(6):e99000. doi: 10.1371/journal.pone.0099000. eCollection 2014.

23.

Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing.

Liang RH, Mo T, Dong W, Lee GQ, Swenson LC, McCloskey RM, Woods CK, Brumme CJ, Ho CK, Schinkel J, Joy JB, Harrigan PR, Poon AF.

Nucleic Acids Res. 2014 Jul;42(12):e98. doi: 10.1093/nar/gku355. Epub 2014 May 7.

24.

Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.

Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, Chopera DR, Brumme CJ, Markle TJ, Martin E, Shahid A, Anmole G, Mwimanzi P, Nassab P, Penney KA, Rahman MA, Milloy MJ, Schechter MT, Markowitz M, Carrington M, Walker BD, Wagner T, Buchbinder S, Fuchs J, Koblin B, Mayer KH, Harrigan PR, Brockman MA, Poon AF, Brumme ZL.

PLoS Genet. 2014 Apr 24;10(4):e1004295. doi: 10.1371/journal.pgen.1004295. eCollection 2014 Apr.

25.

Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.

Sluis-Cremer N, Huber KD, Brumme CJ, Harrigan PR.

Antimicrob Agents Chemother. 2014;58(4):2430-3. doi: 10.1128/AAC.02114-13. Epub 2014 Jan 13.

26.

Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection.

Shimizu A, Kawana-Tachikawa A, Yamagata A, Han C, Zhu D, Sato Y, Nakamura H, Koibuchi T, Carlson J, Martin E, Brumme CJ, Shi Y, Gao GF, Brumme ZL, Fukai S, Iwamoto A.

Sci Rep. 2013 Nov 6;3:3097. doi: 10.1038/srep03097.

27.

A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control.

Bartha I, Carlson JM, Brumme CJ, McLaren PJ, Brumme ZL, John M, Haas DW, Martinez-Picado J, Dalmau J, López-Galíndez C, Casado C, Rauch A, Günthard HF, Bernasconi E, Vernazza P, Klimkait T, Yerly S, O'Brien SJ, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen TM, Müller V, Harrigan PR, Heckerman D, Telenti A, Fellay J.

Elife. 2013 Oct 29;2:e01123. doi: 10.7554/eLife.01123.

28.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

29.

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes.

Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzi P, Omarjee S, Martin E, Lee GQ, Baraki B, Danroth R, McCloskey R, Muzoora C, Bangsberg DR, Hunt PW, Goulder PJ, Walker BD, Harrigan PR, Martin JN, Ndung'u T, Brockman MA, Brumme ZL.

Retrovirology. 2013 Sep 16;10:100. doi: 10.1186/1742-4690-10-100.

30.

Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010.

Cescon A, Kanters S, Brumme CJ, Lepik KJ, Forrest JI, Hull M, Samji H, Nosyk B, Harrigan PR, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):107-14. doi: 10.1097/QAI.0b013e3182a8efc3.

31.

Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.

Brumme CJ, Huber KD, Dong W, Poon AF, Harrigan PR, Sluis-Cremer N.

J Virol. 2013 Aug;87(15):8805-7. doi: 10.1128/JVI.00335-13. Epub 2013 May 29.

32.

"Test-and-treat" strategy for control of HIV and AIDS can lead to a decrease, not an increase, of multidrug-resistant viruses.

Gonzalez-Serna A, Lima VD, Montaner JS, Harrigan PR, Brumme CJ.

Clin Infect Dis. 2013 Aug;57(3):478-9. doi: 10.1093/cid/cit257. Epub 2013 Apr 26. No abstract available.

33.

Influence of HLA-C expression level on HIV control.

Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M.

Science. 2013 Apr 5;340(6128):87-91. doi: 10.1126/science.1232685.

34.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
35.

Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL; International HIV Adaptation Collaborative.

J Virol. 2012 Dec;86(24):13202-16. doi: 10.1128/JVI.01998-12. Epub 2012 Oct 10.

36.

Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay.

Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, Lima VD, Montaner JS, Harrigan PR.

PLoS One. 2012;7(8):e43882. doi: 10.1371/journal.pone.0043882. Epub 2012 Aug 24.

37.

Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals.

Zhang SC, Martin E, Shimada M, Godfrey SB, Fricke J, Locastro S, Lai NY, Liebesny P, Carlson JM, Brumme CJ, Ogbechie OA, Chen H, Walker BD, Brumme ZL, Kavanagh DG, Le Gall S.

J Immunol. 2012 Jun 15;188(12):5924-34. doi: 10.4049/jimmunol.1200219. Epub 2012 May 14.

38.

Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu.

Hasan Z, Carlson JM, Gatanaga H, Le AQ, Brumme CJ, Oka S, Brumme ZL, Ueno T.

Biochem Biophys Res Commun. 2012 May 4;421(2):291-5. doi: 10.1016/j.bbrc.2012.04.002. Epub 2012 Apr 7.

PMID:
22503975
39.

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Brockman MA, Chopera DR, Olvera A, Brumme CJ, Sela J, Markle TJ, Martin E, Carlson JM, Le AQ, McGovern R, Cheung PK, Kelleher AD, Jessen H, Markowitz M, Rosenberg E, Frahm N, Sanchez J, Mallal S, John M, Harrigan PR, Heckerman D, Brander C, Walker BD, Brumme ZL.

J Virol. 2012 Jun;86(12):6913-23. doi: 10.1128/JVI.07133-11. Epub 2012 Apr 11.

40.

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.

PLoS One. 2012;7(3):e34134. doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30.

41.

Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.

Knapp DJ, Brumme ZL, Huang SY, Wynhoven B, Dong WW, Mo T, Harrigan PR, Brumme CJ.

Clin Infect Dis. 2012 Jun;54(11):1652-9. doi: 10.1093/cid/cis253. Epub 2012 Mar 28.

PMID:
22460975
42.

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.

Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM.

PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529. Epub 2012 Mar 8.

43.

Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR.

J Clin Microbiol. 2012 Jun;50(6):1936-42. doi: 10.1128/JCM.06689-11. Epub 2012 Mar 7.

44.

Definition of the viral targets of protective HIV-1-specific T cell responses.

Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreño J, Bach V, Zuniga R, Pérez-Álvarez S, Berger CT, Puertas MC, Martinez-Picado J, Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gómez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C.

J Transl Med. 2011 Dec 7;9:208. doi: 10.1186/1479-5876-9-208.

45.

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington M, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.

J Infect Dis. 2011 Apr 1;203(7):976-83. doi: 10.1093/infdis/jiq143. Erratum in: J Infect Dis. 2011 Aug;204(4):664.

46.

Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, Heckerman D, Wang B, Losina E, Leshwedi M, van der Stok M, Maphumulo L, Mkhwanazi N, Chonco F, Goulder PJ, Essex M, Walker BD, Ndung'u T.

J Virol. 2011 Apr;85(8):3996-4006. doi: 10.1128/JVI.02520-10. Epub 2011 Feb 2.

47.

Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.

Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, Markle TJ, Martin E, Block BL, Trocha A, Kadie CM, Allen TM, Pereyra F, Heckerman D, Walker BD, Brockman MA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):100-8. doi: 10.1097/QAI.0b013e3181fe9450.

48.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

49.

Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection.

Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, Kelleher AD, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Harrigan PR, Heckerman D, Walker BD, Allen TM.

J Virol. 2010 Nov;84(22):11937-49. doi: 10.1128/JVI.01086-10. Epub 2010 Sep 1.

50.

Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters.

Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E, Miura T, Chonco F, van der Stok M, Mncube Z, Bishop K, Goulder PJ, Walker BD, Brockman MA, Ndung'u T.

J Virol. 2010 Oct;84(20):10820-31. doi: 10.1128/JVI.01084-10. Epub 2010 Aug 11.

Supplemental Content

Loading ...
Support Center